Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm, Altus Sign Drug Delivery Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Recipharm, Altus Sign Drug Delivery Pact

To further develop Altus’ patented INTELLITAB™ and FLEXITAB™ drug delivery technologies

By: Betsy Louda

, Contract Pharma

Recipharm has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery technologies and products.

 

Recipharm will co-develop new value added medicines for its customers utilizing Altus’ patented Intellitab and Flexitab drug delivery technologies.

 

Intellitab is a novel misuse and abuse deterrent technology that mitigates the dangers of over-exposure to opioids that can occur due to inadvertent or deliberate tampering with immediate release or extended release narcotics. Intellitab tablets are hardened to resist cutting, crushing and chewing, common methods to accelerate drug release, and spontaneously form hard, stable gels in a range of solvents to deter injection.

 

Flexitab is a commercially validated extended release technology enabling alcohol resistant tablets that maintain their performance after breaking to generate bio-equivalent lower strength tablets. As a result, Flexitab tablets may be broken with no risk of dose dumping or loss of controlled release, eliminating the need for multiple tablets for patients whose regime requires the ability to titrate to effect. 

 

”This collaboration is an exciting step for Recipharm, enabling us to bring innovative drug delivery technologies to our customers and ultimately develop novel, safer and cost effective new products. We look forward to working with Altus to increase the use of its technologies in Europe”, says Bernard Pluta, president of Development Services at Recipharm.

 

”We are delighted to enter into this agreement and look forward to co-developing a range of patent protected, label differentiated new products with Recipharm and its customers,” said Damon Smith, chief executive officer of Altus.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics